• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Methylprednisolone Mylan
    / Genmedix

    Active Ingredient
    Methylprednisolone (as hemisuccinate) 500 mg, 1 g

    Status in Israel

    Presentation and Status in Health Basket

    Presentation Basket Yarpa Pharmasoft


    10 X 500 mg

    not in the basket chart 59192 13504


    10 X 1 g

    not in the basket chart 59191 13503


    The first administration must be done in a hospital. 5 mg of prednisone is equivalent in terms of anti-inflammatory potency to 4 mg of methylprednisolone.
    This proprietary medicinal product is not suitable for inhalation using a nebulizer. This drug is reserved for cases requiring high dose corticosteroid therapy.
    Dosage: Acute symptoms of rheumatoid arthritis, extra-renal symptoms of certain systemic diseases, certain cases of systemic necrotizing vasculitis, initial treatment for certain cases of glomerulopathy: 500 mg to 1 g per day, Organ transplantation, graft rejection: 10 to 15 mg/kg/day, Graft versus host reaction: 10 to 20 mg/kg/day and up to 500 mg/m² every 6 hours for 48 hours. The powder is mixed with water for injections and the resulting solution should be administered intravenously:
    Either directly by slow injection, minimum duration = 20 to 30 minutes. Or by infusion after dilution in isotonic sodium chloride or glucose solution for injection. Such high dose corticosteroid therapy is generally limited to 3 to 5 days.


    When oral therapy is not feasible in endocrine disorders, rheumatic disorders, collagen disease, dermatological conditions, allergic states, ophthalmic disease, GI disease, respiratory disease, haemotologic disorders, neoplastic diseases, edematous states, nervous system and other miscellaneous conditions of adrenocortical deficiency states.


    This drug is generally contraindicated in the following situations: (however, there is no absolute contraindication if corticosteroid therapy is vitally indicated).
    Any infection, Certain active viroses (especially hepatitis, herpes, chickenpox, herpes zoster), Psychotic states not yet controlled by treatment, Live vaccines,
    Hypersensitivity to one of the ingredients. It is generally inadvisable to use this drug in combination with non antiarrhythmic drugs that produce atypical ventricular tachycardia.

    Special Precautions

    Since rare cases of pseudo-anaphylactic reactions have occurred in patients treated with parenteral corticosteroid therapy, special attention must be paid before any administration to subjects presenting with an allergic diathesis.
    Corticosteroid therapy is not contraindicated in cases of peptic ulcer if it is combined with antiulcer treatment. In patients with a history of ulcer, corticosteroid therapy may be prescribed along with clinical surveillance and, if necessary, after fiberendoscopy. Cranial trauma on its own, irrespective of the severity, does not represent an indication for the administration of methylprednisolone hemisuccinate. The results of a multicentre, randomised, placebo-controlled study demonstrated an increase in early (at two weeks) and late (at six months) mortality after a cranial trauma in patients receiving methylprednisolone hemisuccinate in comparison with the placebo group. The causes of the excess mortality in the methylprednisolone group have not been established. Corticosteroid therapy may encourage the appearance of various infectious complications, particularly those caused by bacteria, yeasts and parasites. A major risk is the onset of malignant strongyloidiasis. All subjects arriving from areas where strongyloidiasis is endemic (tropical and subtropical regions, southern Europe) must undergo tests for parasites in stools and receive systematic treatment aimed at eradication prior to corticosteroid therapy. Active signs of an infection may be masked by corticosteroid therapy. Before initiating treatment, it is important to rule out any possibility of a visceral focus (especially tuberculous) and to monitor the onset of infectious diseases during the course of treatment. In cases of earlier tuberculosis, prophylactic antituberculosis treatment is required, if there are appreciable radiological sequelae and if it cannot be confirmed that 6 months of well conducted treatment with rifampicin has been given. The use of corticosteroid therapy requires particularly appropriate monitoring, especially in the elderly and patients with ulcerative colitis (risk of perforation), diverticulitis, recent intestinal anastomoses, renal impairment, hepatic insufficiency, osteoporosis, or myasthenia gravis. Oral or injectable corticosteroids could favour the appearance of tendinopathy, or even a rupture of the tendon (exceptional). This risk increases in case of co-prescription with fluoroquinolones and in dialysed patients with secondary hyperparathyroidism or who have undergone a renal transplant. The attention of sportsmen/women is drawn to the fact that this proprietary medicinal product contains an active substance that might produce a positive reaction in tests carried out during antidoping controls. This medicinal product contains 1.0 mmol (or 41 mg) sodium per dose. To be taken into consideration by patients on a controlled sodium diet
    Precautions for use: The changeover to oral treatment should be initiated as soon as possible. Water and sodium retention normally occurs and is partially responsible for any increase in blood pressure. The patient’s sodium intake must be reduced. Potassium supplementation is only justified with high dose therapy, prescribed for a long period, or if there is a risk of disturbances of rhythm or combination with a potassium-depleting agent. When corticosteroid therapy is essential, diabetes and hypertension are not contraindications, although treatment may cause an imbalance in both cases: their management should be reevaluated. Patients must avoid contact with subjects suffering from chickenpox or measles.

    Side Effects

    Inadvisable combinations
    Drugs inducing atypical ventricular tachycardia:
    astemizole, bepridil, IV erythromycin, halofantrine, pentamidine, sparfloxacin, sultopride, terfenadine, and vincamine. Atypical ventricular tachycardia (hypokalaemia, bradycardia and a pre-existing long Q-T interval are predisposing factors). In cases of hypokalaemia, use substances that do not have the disadvantage of giving rise to atypical ventricular tachycardia.
    Combinations requiring special precautions for use
    Acetylsalicylic acid by the systemic route (and, by extrapolation, other salicylates) Reduction in salicylaemia during corticosteroid therapy and risk of salicylate overdose after its cessation (increased salicylate excretion with corticosteroids). Adjust the salicylate doses while the combination is being used and after the withdrawal of treatment with corticosteroids.
    Antiarrhythmic agents inducing atypical ventricular tachycardia: amiodarone, disopyramide, quinidine-like drugs, and sotalol. Atypical ventricular tachycardia (hypokalaemia, bradycardia and a pre-existing long Q-T interval are predisposing factors).
    Prevention of hypokalaemia and, if necessary, correction: monitor the Q-T interval. If wave bursts occur, do not administer an antiarrhythmic agent (electrical facing).
    Oral anticoagulants Possible impact of corticosteroid therapy on the metabolism of the oral anticoagulant and on that of coagulation factors. Risk of haemorrhage specific to corticosteroid therapy (digestive mucosa, vascular fragility) at high doses or during prolonged treatment for more than 10 days. When the combination is justified, increase surveillance: laboratory controls after 8 days, and then every 15 days during corticosteroid therapy and following its discontinuation.
    Other potassium-depleting agents: potassium-sparing diuretics (alone or in combination), stimulant laxatives, amphotericin B (IV route). Increased risk of hypokalaemia (additive effect). Monitor the serum potassium concentration and, if necessary, correct ; particular attention should be paid if digitalis glycosides are used in treatment.
    Digitalis glycoside: Hypokalaemia enhances the toxic effects of digitalis glycosides. Monitor the serum potassium concentration and, when appropriate, the ECG.
    Heparins (parenteral route): Aggravation by heparin of the haemorrhagic risk intrinsic to corticosteroid therapy (gastrointestinal mucosa, blood vessel fragility) when administered at high doses or over a prolonged period of more than 10 days. Such a combination must be justified and monitoring stepped up.
    Enzyme inducers: Antiepileptic drugs: carbamazepine, phenobarbital, phenytoin, primidone, rifampicin. Reduction in plasma concentrations and efficacy of corticosteroids due to increased hepatic metabolism. The repercussions are of major importance in addisonian and transplant patients. Clinical and laboratory monitoring, and adjustment of corticosteroid dosage during use of the combination and after withdrawal of the enzyme inducer.
    Insulin, metformin, and hypoglycemic sulphonylureas: Elevation in blood glucose, sometimes with ketosis (reduction in carbohydrate tolerance due to corticosteroids). Warn the patient and step up self-monitoring of blood and urine, especially at the start of treatment. Possibly adjust the dosage of antidiabetic during corticosteroid therapy and after its withdrawal.
    Isoniazid (described with prednisolone) Reduction in plasma isoniazid concentrations. Suggested mechanism: increased metabolism of isoniazid in the liver and reduced hepatic metabolism of glucocorticoids. Clinical and laboratory monitoring.
    Combinations to be taken into consideration: Antihypertensives Reduction in the antihypertensive effect (water and sodium retention due to corticosteroids), Ciclosporin Possible increase in plasma ciclosporin and creatinine concentrations. Proposed mechanism: reduction in hepatic elimination of ciclosporin, Fluoroquinolones Possible increase of the risk of tendinopathy, or even rupture of the tendon (exceptional), especially in patients who receive a long-term corticosteroid therapy. Interferon alfa Risk of inhibiting the action of interferon, Attenuated live vaccines Risk of generalized, possibly lethal, disease. The risk is increased in subjects who are already immunocompromised by the underlying disease, Use an inactivated vaccine when available (poliomyelitis).

    Drug interactions

    Phenytoin, barbiturates, carbamazepine, aminoglutethimide, rifampicin. Thiazide and loop diuretics, cardiac glycosides, acetazolamide. Oral hypoglycemics, insulin, antihypertensives, anabolic steroids, ophthalmic idoxuridine. NSAIDs, aspirin, other salicylates, coumarin anticoagulants, vaccines, estrogens.

    Pregnancy and Lactation

    Pregnancy: A teratogenic effect – which varies according to the species considered – has been found in animal experiments. The drug crosses the placenta in pregnant women. However, epidemiological studies have failed to detect any risk of malformation related to the administration of corticosteroids during the first trimester of pregnancy. Slight intrauterine growth retardation may occur when chronic diseases require treatment throughout pregnancy. Neonatal adrenal insufficiency has been observed in rare cases after high-dose corticosteroid therapy. A period of laboratory and clinical monitoring (weight and urinary output) is justified in neonates. Consequently, corticosteroids may be prescribed during pregnancy if necessary.
    Lactation: Lactation is inadvisable during long-term and high-dose therapy.


    There is no specific antidote in cases of massive overdose: treatment is basically symptomatic. In a hospital setting, doses ranging up to 30 mg/kg are used for slow I.V. injection (minimum duration = 20 minutes) during short term corticosteroid therapy. Signs of adrenocortical hyperfunction may possibly occur, as with any high-dose, long-term corticosteroid therapy, particularly disturbances in carbohydrate metabolism, tetany due to hypocalcaemia, cushingoid appearance, and mental excitement. These disturbances can usually be reversed merely by decreasing the doses or discontinuing treatment. Methylprednisolone is dialyzable.

    MYLAN S.A.S, France
    Licence holder